Skip to main content
Equibles
ENTX logo

ENTX · Entera Bio Ltd.

Track ENTX — free

Use ENTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ENTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.03 -0.05 (-1.62%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — cleared Aug 7, 2026

The latest filing states the doubt was alleviated.

“Following the closing of the private placement and receipt of the related net proceeds, management concluded that substantial doubt about the Company's ability to continue as a going concern no longer exists.”
View the 10-Q filed Aug 7, 2026
Market Cap
$533.28M
Shares
173.14M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-10-12 00:00 UTC The American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Shareholder meeting

Past events

Date Event Type
2026-08-12 Canaccord Genuity 46th Annual Growth Conference (Fireside Chat and 1x1 Meetings) Conference
2026-06-15 Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism Event
2026-06-14 Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study Event
2026-06-13 EB618, First-in-Class Oral Tablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and Metabolic Disorders: Results from PK-PD Study in Non-Human Primates Event
2026-04-20 Key Opinion Leader Virtual Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 Event
2025-12-03 8th Annual Evercore ISI HealthCONx Conference (Fireside Chat and 1x1 Meetings) Conference
2025-10-25 The Menopause Society 2025 Annual Meeting (Poster) Shareholder meeting
2025-09-13 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress (Poster) Event
2025-09-07 American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting (Poster and 1×1) Shareholder meeting
2025-09-05 American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting (Oral Presentation) Shareholder meeting
2025-09-05 H.C. Wainwright 27th Annual Global Investment Conference (Presentation) Conference
2025-07-13 ENDO 2025 annual meeting of the Endocrine Society Shareholder meeting
2025-06-19 2025 BIO International Convention Event
2025-04-13 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Event
2025-04-11 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Event
2025-03-12 Leerink Partners Global Healthcare Conference Conference
2025-02-11 Oppenheimer 35th Annual Healthcare Life Sciences Conference Conference

Source: https://investors.enterabio.com/

Key facts CIK 1638097 CUSIP M40527109 13F (30d) 31 filings 30 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)